Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes
The DOI matches its Crossref record; 55 of the 56 references it cites were found in a registry or an index.
Abstract
Transfection of embryo fibroblasts by a human ras oncogene does not convert them into tumour cells unless the fibroblasts are established and immortalized before transfection. The embryo fibroblasts become tumorigenic if a second oncogene such as a viral or cellular myc gene or the gene for the polyoma large-T antigen is introduced together with the ras gene.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, transformation of primary cells by ras requires either a cooperating oncogene or the inactivation of tumor suppressors such as p53 or p16.”
From Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a (1997) · cites this paper as Land et al. 1983
In the citing paper
“ras cooperates, however, with certain other oncogenic alterations to transform primary rodent cells (Land et al. 1983; Ruley 1983), including overexpression of c-Myc, dominant negative p53, D-type cyclins, and Cdc25A and -B, and loss of p53, p16, or IRF-1”
From Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a (1997) · cites this paper as Land et al. 1983
In the citing paper
“In that setting, dysfunctional telomeres induced a strong cellular senescence phenotype in the emerging lymphomas resulting in potent suppression of lymphomagenesis.”
From Telomeres and telomerase in cancer (2010) · cites this paper as [93]
Citations
Cites
A new technique for the assay of infectivity of human adenovirus 5 DNA
Graham, F. L., & van der Eb, A. J. (1973) · Virology · doi:10.1016/0042-6822(73)90341-3 · Cited by 9,451
Dalla-Favera, R., Bregni, M., Erikson, J., Patterson, D., Gallo, R. C., & Croce, C. M. (1982) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.79.24.7824 · Cited by 1,773
Mutation selection and the natural history of cancer
Cairns, J. (1975) · Nature · doi:10.1038/255197a0 · Cited by 1,582
Activation of a cellular onc gene by promoter insertion in ALV-induced lymphoid leukosis
Hayward, W. S., Neel, B. G., & Astrin, S. M. (1981) · Nature · doi:10.1038/290475a0 · Cited by 1,567
Taub, R., Kirsch, I., Morton, C., Lenoir, G., Swan, D., Tronick, S., Aaronson, S., & Leder, P. (1982) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.79.24.7837 · Cited by 1,422
Mechanism of activation of a human oncogene
Tabin, C. J., Bradley, S. M., Bargmann, C. I., Weinberg, R. A., Papageorge, A. G., Scolnick, E. M., Dhar, R., Lowy, D. R., & Chang, E. H. (1982) · Nature · doi:10.1038/300143a0 · Cited by 1,393
Self-citationRuley, H. E. (1983) · Nature · doi:10.1038/304602a0 · Cited by 1,248
Mulligan, R. C., & Berg, P. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.4.2072 · Cited by 982
Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras gene
Parada, L. F., Tabin, C. J., Shih, C., & Weinberg, R. A. (1982) · Nature · doi:10.1038/297474a0 · Cited by 944
Self-citationDer, C. J., Krontiris, T. G., & Cooper, G. M. (1982) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.79.11.3637 · Cited by 800
Research works printed but not linked: 9
- Berenblum, I. & Shubik, P. Br. J. Cancer 1, 388 (1947).
- Emmelot, P. & Scherer, E. Cancer Res. 37, 1702–1708 (1977).
- Crawford, B. D., Barrett, J. C. & Ts'o, P. O. P. Molec. cell. Biol. 3, 931–945 (1983). · doi:10.1128/mcb.3.5.931
- Murray, M. J. et al. Cell (in the press).
- Aaronson, S. A. & Todaro, G. J. J. Cell Biol. 72, 141–148 (1968).
- Perucho, M., Hanahan, D. & Wigler, M. Cell 22, 309–317 (1980). · DOI · Paper page
- Beard, J. W. in Viral Oncology (ed. Klein, G.) 55–88 (Raven, New York, 1980).
- Adams, J. M., Gerondakis, S., Webb, E., Corcoran, L. & Cory, S. Proc. natn. Acad. Sci. U.S.A. (in the press).
- Gross, L. Oncogenic viruses, 931 (Pergamon, Oxford, 1970).
Cited by
Items 701–800 of 1,010
Cytomegalovirus infection and viral‐induced transformation of human endothelial cells
Smiley, M. L., Mar, E., & Huang, E. (1988) · Journal of Medical Virology · doi:10.1002/jmv.1890250212 · Cited by 93
Surface IgM mediated regulation of RAG gene expression in E mu‐N‐myc B cell lines.
Ma, A. I., Fisher, P. E., Dildrop, R., Oltz, E. M., Rathbun, G. A., Achacoso, P., Stall, A. M., & Alt, F. W. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05338.x · Cited by 87
Schneider, M. D., Perryman, M. B., Payne, P. A., Spizz, G., Roberts, R., & Olson, E. N. (1987) · Molecular and Cellular Biology · doi:10.1128/mcb.7.5.1973 · Cited by 87
Interactions between cell growth-regulating domains in the products of the adenovirus E1A oncogene.
Moran, B., & Zerler, B. (1988) · Molecular and Cellular Biology · doi:10.1128/mcb.8.4.1756 · Cited by 88
Familial Multiple Cervical Paragangliomas: Report of a Kindred and Review of the Literature
Sobol, S. M., & Dailey, J. C. (1990) · Otolaryngology · doi:10.1177/019459989010200413 · Cited by 86
Yang, G., Timme, T. L., Frolov, A., Wheeler, T. M., & Thompson, T. C. (2005) · Cancer · doi:10.1002/cncr.20905 · Cited by 86
“firmly in the pioneering studies of oncogenic collaboration.(51) In addition to caveolin-1 up-regulation, a”
BackgroundCudré-Mauroux, C., Occhiodoro, T., König, S., Salmon, P., Bernheim, L., & Trono, D. (2003) · Human Gene Therapy · doi:10.1089/104303403322495034 · Cited by 87
Russo, J., Reina, D., Frederick, J. J., & Russo, I. H. (1988) · PubMed · Cited by 93
Screaton, R. A., Penn, L. Z., & Stanners, C. P. (1997) · The Journal of Cell Biology · doi:10.1083/jcb.137.4.939 · Cited by 86
“Cellular transformation induced by c-myc deregulation is, however, often incomplete and depends on the activation of another oncogene, such as ras (Land et al., 1983; Adams et al., 1985).”
Lord, J. D., McIntosh, B. C., Greenberg, P. D., & Nelson, B. H. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.9.4627 · Cited by 96
“The rasprotein is normally activated downstream of Grb2, and constitutively active versions of rashave been shown to mediatebcl-2andbcl-x induction and, when coexpressed with c-myc, promote proliferation (49, 50).”
BackgroundSchuster, R., Gerlich, W. H., & Schaefer, S. (2000) · Oncogene · doi:10.1038/sj.onc.1203417 · Cited by 86
“S (pC53-249) (Ponchel et al., 1994); c-Ha-ras (pEJ-ras) and c-myc (Land et al., 1983); SV40-TAg (pCMV-T) (Dimri et al., 1996); human Bcl-2 (bcl2-pSFFV-neo) (Cuende et al., 1993), baculovirus p35 (p35-pSFFV-neo) (Qi et al., 1997); adenovirus E1B (pCMVE1B) (White et al., 1991), and cowpox protein…”
MethodThe first exon of the c‐myc proto‐oncogene contains a novel positive control element.
Yang, J.-P., Remmers, E. F., & Marcu, K. B. (1986) · The EMBO Journal · doi:10.1002/j.1460-2075.1986.tb04682.x · Cited by 91
Coll, J., Righi, M., de Taisne, C., Dissous, C., Gégonne, A., & Stéhelin, D. (1983) · The EMBO Journal · doi:10.1002/j.1460-2075.1983.tb01722.x · Cited by 86
Tumor suppression by p53: making cells senescent.
Qian, Y., & Chen, X. (2010) · PubMed · doi:10.14670/hh-25.515 · Cited by 85
“Combined activation of Ras with a cooperating oncogene, such as Myc, E1A, and SV40 large T antigen (Land et al., 1983, Ruley, 1983), or with loss of a tumor suppressor, such as p53 and p16, leads to transformation of primary cells and tumor formation in animals (Kemp et al., 1993, Chintala et al.,…”
Park, S., Zhu, Y., Özden, Ö., Kim, H. S., Jiang, H., Deng, C., Gius, D. R., & Vassilopoulos, A. (2012) · PubMed · Cited by 108
p38α and p38γ Mediate Oncogenic ras-induced Senescence through Differential Mechanisms
Kwong, J., Hong, L., Liao, R., Deng, Q., Han, J., & Sun, P. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m808327200 · Cited by 82
Recruitment of TRRAP required for oncogenic transformation by E1A
Deleu, L., Shellard, S. A., Alevizopoulos, K., Amati, B. B., & Land, H. (2001) · Oncogene · doi:10.1038/sj.onc.1205159 · Cited by 96
“Cotransfections were carried out with 5 mg of pUC±Ha-Ras (Land et al., 1983), 5 mg of the pBJ4 ±E1A±Myc chimeras or 5 mg of pBabe Hygro E1A and 1 mg of pJ6 omega Puro.”
MethodSelf-citationAdenovirus Type 5 E1A Gene Products Act as Transformation Suppressors of the neu Oncogene
Yu, D., Scorsone, K. A., & Hung, M. (1991) · Molecular and Cellular Biology · doi:10.1128/mcb.11.3.1745 · Cited by 87
Koi, M., & Barrett, J. C. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.16.5992 · Cited by 85
Oncogene expression in human leukemia
Blick, M. B., Westin, E., Gutterman, J., Wong-Staal, F., Gallo, R. C., McCredie, K., Keating, M. J., & Murphy, E. (1984) · Blood · doi:10.1182/blood.v64.6.1234.1234 · Cited by 89
Mechanisms of Signal Transduction to the Cell Nucleus
Nigg, E. A. (1990) · Advances in cancer research · doi:10.1016/s0065-230x(08)60471-6 · Cited by 95
Akt is required for Axl-Gas6 signaling to protect cells from E1A-mediated apoptosis
Lee, W.-P., Wen, Y., Varnum, B. C., & Hung, M. (2002) · Oncogene · doi:10.1038/sj.onc.1205066 · Cited by 84
“…oncogene because of the fact that some transforming oncogenes, such as ras and E1B, although able to induce transformation of immortalized rodent cell lines (established cell lines), require E1A to transform cells in primary cultures (Byrd et al., 1988; Land et al., 1983; Ruley, 1983).”
BackgroundImmortalization and Transformation of Human Cells
C. Hahn, W. (2002) · Molecules and Cells · doi:10.1016/s1016-8478(23)15045-x · Cited by 84
Somatic cell fusion as a source of genetic rearrangement leading to metastatic variants
Larizza, L., & Schirrmacher, V. (1984) · Cancer and Metastasis Reviews · doi:10.1007/bf00048385 · Cited by 84
Loss of USF transcriptional activity in breast cancer cell lines
Ismail, P. M., Lu, T., & Sawadogo, M. (1999) · Oncogene · doi:10.1038/sj.onc.1202932 · Cited by 84
“…10 December 1998; revised 13 April 1999; accepted 22 April 1999 Oncogene (1999) 18, 5582 ± 5591 ã 1999 Stockton Press All rights reserved 0950 ± 9232/99 $15.00 http://www.stockton-press.co.uk/onc primary cells when coexpressed with a second oncoprotein such as activated Ras (Land et al., 1983).”
BackgroundInfluentialThei, T., MacLean-Hunter, S., rnig, M. Z. O., & Möröy, T. (1993) · Nucleic Acids Research · doi:10.1093/nar/21.25.5921 · Cited by 84
Powell, M. B., Hyman, P., Bell, O. D., Balmain, A., Brown, K., Alberts, D., & Bowden, G. T. (1995) · Molecular Carcinogenesis · doi:10.1002/mc.2940120205 · Cited by 84
Cherington, V, Brown, M., Paucha, E., St Louis, J., Spiegelman, B. M., & Roberts, T. M. (1988) · Molecular and Cellular Biology · doi:10.1128/mcb.8.3.1380 · Cited by 84
Distinctive transforming genes in x-ray-transformed mammalian cells.
Borek, C., Ong, A., & Mason, H. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.3.794 · Cited by 84
Regulation of Bcl-2 gene expression by BCR-ABL is mediated by Ras
Sánchez-Garcı́a, I., & Martı́n-Zanca, D. (1997) · Journal of Molecular Biology · doi:10.1006/jmbi.1996.0779 · Cited by 84
Oskarsson, T., Essers, M. A. G., Dubois, N., Offner, S., Dubey, C., Roger, C., Metzger, D., Chambon, P., Hummler, E., Beard, P., et al. (2006) · Genes & Development · doi:10.1101/gad.381206 · Cited by 82
“In addition, c-Myc-induced tumorigenesis using K5 c-Myc transgene is inhibited when animals were bred onto a CDK4-deficient background (Miliani de Marval et al. 2004).”
BackgroundMYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer
Casacuberta‐Serra, S., González-Larreategui, Í., Capitán-Leo, D., & Soucek, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01907-z · Cited by 100
“Importantly, MYC and RAS interplay is the paradigm of oncogene cooperation, 28 starting from the fi rst demonstration of their interdependence in 1983, 29 until the most recent data on their joint role in immune suppression.”
BackgroundEffects of rearrangement and allelic exclusion of JJAZ1 / SUZ12 on cell proliferation and survival
Li, H., Ma, X., Wang, J., Koontz, J., Nucci, M., & Sklar, J. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709986104 · Cited by 82
Liebermann, D. A., & Hoffman‐Liebermann, B. (2002) · Leukemia · doi:10.1038/sj.leu.2402477 · Cited by 91
Kacinski, B. M., Carter, D., Mittal, K., Kohorn, E. I., Bloodgood, R., Donahue, J. K., DONOFRIO, L. M., Edwards, R., Schwartz, P. E., Chambers, J. T., et al. (1988) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(88)90113-7 · Cited by 83
Kelekar, A., & Cole, M. D. (1986) · Molecular and Cellular Biology · doi:10.1128/mcb.6.1.7 · Cited by 83
Butel, J. S., & Jarvis, D. L. (1986) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(86)90027-2 · Cited by 83
Subversion of growth regulatory pathways in malignant transformation
Heldin, C., Betsholtz, C., Claesson, L., & Westermark, B. (1987) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(87)90007-2 · Cited by 91
Small DNA tumor viruses: Large contributors to biomedical sciences
Howley, P. M., & Livingston, D. M. (2009) · Virology · doi:10.1016/j.virol.2008.12.006 · Cited by 78
“The notion of cooperating oncogenes was subsequently extended to cellular oncogenes, such as myc and ras (Land, Parada, and Weinberg, 1983).”
BackgroundSheng, W., Decaussin, G., Sumner, S., & Ooka, T. (2001) · Oncogene · doi:10.1038/sj.onc.1204217 · Cited by 82
“Studies realized on the molecular basis for multi-step transformation have demonstrated that at least a part of this process comes from the cooperative action of several oncogenes (Land et al., 1983).”
BackgroundInflammation, Oxidative DNA Damage, and Carcinogenesis
Lewis, J. G., & Adams, D. O. (1987) · Environmental Health Perspectives · doi:10.1289/ehp.877619 · Cited by 82
Campo, M. S., Moar, M. H., Sartirana, M. L., Kennedy, I. M., & Jarrett, W. F. H. (1985) · The EMBO Journal · doi:10.1002/j.1460-2075.1985.tb03856.x · Cited by 82
Oncogene-Induced Transformation of C3H 10T1/2 Cells Is Enhanced by Tumor Promoters
Hsiao, W. L. W., Gattoni‐Celli, S., & Weinstein, I. B. (1984) · Science · doi:10.1126/science.6436974 · Cited by 82
RAS as Supporting Actor in Breast Cancer
Galiè, M. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01199 · Cited by 91
“RAS protein overexpression, hyperactivation of upstream RAS activators, such as receptor tyrosine kinases, perturbation in the activity of RAS regulators, such as GEFs and GAPS, all may contribute to promote and sustain tumorigenicity (50, 51).”
BackgroundKelekar, A., & Cole, M. D. (1987) · Molecular and Cellular Biology · doi:10.1128/mcb.7.11.3899 · Cited by 81
Activation Domains of L-Myc and c-Myc Determine Their Transforming Potencies in Rat Embryo Cells
Barrett, J., Birrer, M. J., Kato, G. J., Dosaka‐Akita, H., & Dang, C. V. (1992) · Molecular and Cellular Biology · doi:10.1128/mcb.12.7.3130 · Cited by 81
An in vivo function for the transforming Myc protein: elicitation of the angiogenic phenotype.
Ngo, C., Gee, M. F. W., Akhtar, N., Yu, D., Volpert, O. V., Auerbach, R., & Thomas‐Tikhonenko, A. (2000) · PubMed · Cited by 81
Cytogenetic and pathologic aspects of Ewing's sarcoma and neuroectodermal tumors
Stephenson, C. F., Bridge, J. A., & Sandberg, A. A. (1992) · Human Pathology · doi:10.1016/0046-8177(92)90295-e · Cited by 81
Obberghen‐Schilling, E. V., Chambard, J., Paris, S., L’Allemain, G., & Pouysségur, J. (1985) · The EMBO Journal · doi:10.1002/j.1460-2075.1985.tb04025.x · Cited by 84
Expression of Cellular Oncogenes
Müller, R., & Verma, I. M. (1984) · Current topics in microbiology and immunology · doi:10.1007/978-3-642-69677-0_4 · Cited by 86
Transcriptional Activation by the Myc Oncoprotein
Cole, M. D., & Nikiforov, M. A. (2006) · Springer eBooks · doi:10.1007/3-540-32952-8_2 · Cited by 92
Antagonistic control of cell fates by JNK and p38-MAPK signaling
Wada, T., Stępniak-Konieczna, E., Hui, L., Leibbrandt, A., Katada, T., Nishina, H., Wagner, E. F., & Penninger, J. M. (2007) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4402222 · Cited by 80
Chen, T. H., Brody, J. R., Romantsev, F. E., Yu, J. G., Kayler, A. E., Voneiff, E., Kuhajda, F. P., & Pasternack, G. R. (1996) · Molecular Biology of the Cell · doi:10.1091/mbc.7.12.2045 · Cited by 80
Molecular Markers of IGF-I-Mediated Mitogenesis
Reiss, K., Valentinis, B., Tu, X., Xu, S., & Baserga, R. (1998) · Experimental Cell Research · doi:10.1006/excr.1998.4113 · Cited by 87
Vennström, B., Kahn, P., Adkins, B., Enrietto, P. J., Hayman, M. J., Graf, T., & Luciw, P. A. (1984) · The EMBO Journal · doi:10.1002/j.1460-2075.1984.tb02282.x · Cited by 80
Suppression of tumorigenicity in hybrids of normal and oncogene-transformed CHEF cells.
Craig, R. W., & Sager, R. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.7.2062 · Cited by 80
Cell cycle activity and expression of prohibitin mRNA
Roskams, A. J., Friedman, V., Wood, C. M., Walker, L., Owens, G. A., Stewart, D. A., Altus, M. S., Danner, D. B., Liu, X., & McClung, J. K. (1993) · Journal of Cellular Physiology · doi:10.1002/jcp.1041570211 · Cited by 79
Schaffner, D. L., Barrios, R. J., Massey, C. T., Banez, E., Ou, C. N., Rajagopalan, S., Aguilar-Córdova, E., Lebovitz, R. M., Overbeek, P. A., & Lieberman, M. W. (1993) · PubMed Central · Cited by 79
Analysis of the Role of bcl‐2 in Apoptosis
Hawkins, C. J., & Vaux, D. L. (1994) · Immunological Reviews · doi:10.1111/j.1600-065x.1994.tb00886.x · Cited by 79
“As activated ras genes could transform NIH 3T3 fibroblasts (Land et al. 1983), we first looked to see if bcl-2 could do the same.”
BackgroundMolecular Genetic Analysis of Human Lymphoid Neoplasms
Waldmann, T. A., Korsmeyer, S. J., BAKHSHI, A., ARNOLD, A., & KIRSCH, I. R. (1985) · Annals of Internal Medicine · doi:10.7326/0003-4819-102-4-497 · Cited by 79
‘Nuclear’ oncogenes convert extracellular stimuli into changes in the genetic program
Herrlich, P. A., & Ponta, H. (1989) · Trends in Genetics · doi:10.1016/0168-9525(89)90041-3 · Cited by 95
Oncoapoptotic signaling and deregulated target genes in cancers: Special reference to oral cancer
Khan, Z., & Bisen, P. S. (2013) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2013.04.002 · Cited by 90
“In a classic study, Weinberg and co-workers has been demonstrated that c-Myc in collaboration with activated Ras was able to transform primary fibroblasts [102].”
BackgroundTrosko, J. E., & Tai, M.-H. (2006) · KARGER eBooks · doi:10.1159/000092965 · Cited by 87
Suppression of MYC by high expression of NMYC in human neuroblastoma cells
Breit, S., & Schwab, M. (1989) · Journal of Neuroscience Research · doi:10.1002/jnr.490240105 · Cited by 79
“All three MYC genes have been shown to assist mutationally activated c-Haras in tumorigenic conversion of primary rat embryo cells (Land et al., 1983; Schwab et al., 1985; DePinho et al., 1987).”
BackgroundSilic‐Benussi, M., Cavallari, I., Zorzan, T., Rossi, E. M. C., Hiraragi, H., Rosato, A., Horie, K., Saggioro, D., Lairmore, M. D., Willems, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0305502101 · Cited by 86
c-Myc cooperates with activated Ras to induce the cdc2 promoter.
Born, T. L., Frost, J. A., Schönthal, A., Prendergast, G. C., & Feramisco, J. R. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.9.5710 · Cited by 77
Palmieri, S., Kahn, P., & Graf, T. (1983) · The EMBO Journal · doi:10.1002/j.1460-2075.1983.tb01750.x · Cited by 78
Expression of the Epstein-Barr virus nuclear protein 2 in rodent cells
Dambaugh, T. R., Wang, F., Hennessy, K., Woodland, E., Rickinson, A. B., & Kieff, E. D. (1986) · Journal of Virology · doi:10.1128/jvi.59.2.453-462.1986 · Cited by 78
“Rat-1-LMP 37 (26-47) >104 Rat-1-NEO-1 0 < 100”
MethodKim, Y. C., Song, K.-S., Yoon, G., Nam, M., & Ryu, W. (2001) · Oncogene · doi:10.1038/sj.onc.1203840 · Cited by 77
“The initial paradigm of this cooperation is the one between ras and myc oncogene (Land et al., 1983).”
BackgroundMethodInfluentialWasylishen, A. R., & Penn, L. Z. (2010) · Genes & Cancer · doi:10.1177/1947601910378024 · Cited by 90
Chang, C., Trosko, J. E., El‐Fouly, M. H., Gibson‐D'Ambrosio, R. E., & D’Ambrosio, S. M. (1987) · PubMed · Cited by 77
Histone H5 in the Control of DNA Synthesis and Cell Proliferation
Sun, J.-M., Wiaderkiewicz, R., & Ruiz-Carrillo, A. (1989) · Science · doi:10.1126/science.2740916 · Cited by 77
Schreiber‐Agus, N., Horner, J. W., TORRES, R. A., Chiu, F., & DePinho, R. A. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.5.2765 · Cited by 77
Recombinant Interleukin 2 Regulates Levels of c- myc mRNA in a Cloned Murine T Lymphocyte
Reed, J. C., Sabath, D. E., Hoover, R. G., & Prystowsky, M. B. (1985) · Molecular and Cellular Biology · doi:10.1128/mcb.5.12.3361 · Cited by 77
Paris, S., Chambard, J., & Pouysségur, J. (1987) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)61607-2 · Cited by 78
From 2D to 3D and beyond: the evolution and impact of in vitro tumor models in cancer research
Rauner, G., Gupta, P. B., & Kuperwasser, C. (2025) · Nature Methods · doi:10.1038/s41592-025-02769-1 · Cited by 87
“They were crucial in defining the genetic and signaling pathways required for cancer development, and contributed to understanding the cellular mechanisms of senescence, apoptosis and autophagy 32,36 .”
Formigli, L., Papucci, L., Tani, A., Schiavone, N., Tempestini, A., Orlandini, G. E., Capaccioli, S., & Zecchi Orlandini, S. (2000) · Journal of Cellular Physiology · doi:10.1002/(sici)1097-4652(200001)182:1<41::aid-jcp5>3.0.co;2-7 · Cited by 370
The coupling of cell growth to the cell cycle
Tapon, N., Moberg, K. H., & Hariharan, I. K. (2001) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(00)00284-2 · Cited by 79
Lynch, M., Fitzgerald, C., Johnston, K. A., Wang, S., & Schmidt, E. V. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m310872200 · Cited by 73
c-Myc in the Controlm of Cell Proliferation and Embryonic Development
Lemaître, J.-M., Buckle, R. S., & Méchali, M. (1996) · Advances in cancer research · doi:10.1016/s0065-230x(08)60873-8 · Cited by 86
Yamada, H., Sakamoto, H., Taira, M., Nishimura, S., Shimosato, Y., Terada, M., & Sügimura, T. (1986) · PubMed · Cited by 76
Cancer genes: rare recombinants instead of activated oncogenes (a review).
DUESBERG, P. H. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.8.2117 · Cited by 76
NDF induces expression of a novel 46 kD protein in estrogen receptor positive breast cancer cells
Kumar, R., Mandal, M., Ratzkin, B. J., Liu, N., & Lipton, A. (1996) · Journal of Cellular Biochemistry · doi:10.1002/(sici)1097-4644(199607)62:1<1::aid-jcb1>3.0.co;2-x · Cited by 12
Biology of gliomas: heterogeneity, oncogenes, growth factors.
Shapiro (1986) · PubMed · Cited by 79
Oncogenes and proto-oncogenes: How do they differ?
Hunter, T. R. (1984) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/73.4.773 · Cited by 84
PI3K: A Crucial Piece in the RAS Signaling Puzzle
Krygowska, A. A., & Castellano, E. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031450 · Cited by 84
“Wild-type RAS proteins are crucial for several physiological processes, but it is their involvement in cancer that has attracted the most attention (Land et al. 1983a,b; Ruley 1983; Trahey and McCormick 1987; Hirakawa and Ruley 1988).”
BackgroundThe Role and Function of Ras-association domain family in Cancer: A Review
Zinatizadeh, M. R., Momeni, S. A., Zarandi, P. K., Chalbatani, G. M., Dana, H., Mirzaei, H. R., Akbari, M. E., & Miri, S. R. (2019) · Genes & Diseases · doi:10.1016/j.gendis.2019.07.008 · Cited by 79
“At first, there was disagreement on the physiological nature of interaction between Ras and RASSF1, but some groups suggested that there is no direct interaction between them.(18) However, some studies reported that Ras forms an endogenous complex with RASSF1 with a direct interaction.”
BackgroundDevelopment of intestinal cell culture models for drug transport and metabolism studies
Quaroni, A., & Hochman, J. H. (1996) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00413-9 · Cited by 92
cis-Acting Translational Effects of the 5′ Noncoding Region of c-myc mRNA
Parkin, N. T., Darveau, A., Nicholson, R., & Sonenberg, N. (1988) · Molecular and Cellular Biology · doi:10.1128/mcb.8.7.2875 · Cited by 89
Masutomi, K., & Hahn, W. C. (2003) · Cancer Letters · doi:10.1016/s0304-3835(02)00703-6 · Cited by 83
Synergism of v- myc and v-Ha- ras in the in Vitro Neoplastic Progression of Murine Lymphoid Cells
Schwartz, R. C., Stanton, L. W., Riley, S. C., Marcu, K. B., & Witte, O. N. (1986) · Molecular and Cellular Biology · doi:10.1128/mcb.6.9.3221 · Cited by 75
Neoplastic Conversion of Human Keratinocytes by Adenovirus 12-SV40 Virus and Chemical Carcinogens
Rhim, J. S., Fujita, J., Arnstein, P., & Aaronson, S. A. (1986) · Science · doi:10.1126/science.2421406 · Cited by 75
Vousden, K. H., Eccles, S. A., Purvies, H. P., & Marshall, C. J. (1986) · International Journal of Cancer · doi:10.1002/ijc.2910370315 · Cited by 75
Su, L., Hershberger, R. J., & Weissman, I. L. (1993) · Genes & Development · doi:10.1101/gad.7.5.735 · Cited by 84
“lignant one (Land et al. 1983; Weinberg 1989).”
BackgroundMYC-driven synthesis of Siglec ligands is a glycoimmune checkpoint
Smith, B. A. H., Deutzmann, A., Correa, K. M., Delaveris, C. S., Dhanasekaran, R., Dove, C. G., Sullivan, D. K., Wisnovsky, S., Stark, J. C., Pluvinage, J. V., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2215376120 · Cited by 81
“For example, RAS cooperates with MYC to promote oncogenesis (97), and RAS activation creates a pool of stabilized, active MYC (98).”
T cell cultures and the Hayflick limit
Effros, R. B., & Walford, R. L. (1984) · Human Immunology · doi:10.1016/0198-8859(84)90006-5 · Cited by 74
Yamada, H., Yoshida, T., Sakamoto, H., Terada, M., & Sügimura, T. (1986) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(86)91072-7 · Cited by 74
Johnson, K. R., Disney, J., Wyatt, C. R., & Reeves, R. (1990) · Experimental Cell Research · doi:10.1016/0014-4827(90)90118-t · Cited by 77
Structure and expression of the murine L‐myc gene.
Legouy, E., DePinho, R. A., Zimmerman, K., Collum, R. G., Yancopoulos, G. D., Mitsock, L., Kriz, R., & Alt, F. W. (1987) · The EMBO Journal · doi:10.1002/j.1460-2075.1987.tb02657.x · Cited by 74
Chen, T. A., Sterner, R., Cozzolino, A., & Allfrey, V. G. (1990) · Journal of Molecular Biology · doi:10.1016/0022-2836(90)90327-i · Cited by 74
Metadata
- Authors
- Land, H., Parada, L. F., & Weinberg, R. A.
- Affiliations
- Whitehead Institute for Biomedical Research (US)
- Venue
- Nature
- Published
- 1983-08
- Volume
- 304
- Issue
- 5927
- Pages
- 596-602
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1989009382
- Cited by
- 2,804
- References
- 56
- Citations by year
- 2026: 8 · 2025: 13 · 2024: 22 · 2023: 15 · 2022: 17 · 2021: 24 · 2020: 22 · 2019: 36 · 2018: 17 · 2017: 23 · 2016: 24 · 2015: 39 · 2014: 27 · 2013: 30 · 2012: 37
- FWCI
- 96.77
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and Retrovirus Studies
- Keywords
- embryonic fibroblasts, oncogene cooperation, oncogenic Ras, MYC gene, polyomavirus large T antigen, cell immortalization, transfection
- MeSH terms
- Animals, Antigens, Viral, Antigens, Viral, Tumor, Cell Line, Cell Transformation, Viral, Cells, Cultured, Fibroblasts, Gene Expression Regulation, Genes, Viral, Genetic Complementation Test, Oncogenes, Phenotype, Polyomavirus, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.